ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity
Status:
Terminated
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
This is a 16-week randomized, double-blind, parallel-group, multi-center, placebo- and
active- (metformin 1.5 g) controlled study of tesaglitazar (1 mg) in patients with type 2
diabetes. After a 1-week enrollment period, a 3 week placebo single blind run in period and
1-week placebo single-blind baseline measurement period, the patients will be given the
investigational product for 16 weeks in a double blind fashion. Metformin will be titrated up
during the first 3 weeks of the double-blind period. The total study duration, including
enrollment, run-in, randomized treatment and follow-up, is 29 weeks.